| Literature DB >> 9784112 |
D H Boschelli1, Z Wu, S R Klutchko, H D Showalter, J M Hamby, G H Lu, T C Major, T K Dahring, B Batley, R L Panek, J Keiser, B G Hartl, A J Kraker, W D Klohs, B J Roberts, S Patmore, W L Elliott, R Steinkampf, L A Bradford, H Hallak, A M Doherty.
Abstract
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9784112 DOI: 10.1021/jm980398y
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446